Most Recent

Background: Burn wound repair is driven by oxidative balance and keratinocyte regeneration. Polyphenol-rich botanicals are considered promising due to combined antioxidant and pro-regenerative properties. This study compares four ethnopharmacological...

In 2025, the FDA approved 46 novel drugs, including four TIDEs (one peptide, three oligonucleotides, and one antibody drug conjugate containing peptide as a payload). The three approved oligonucleotide therapeutics—fitusiran, donidalorsen, and...

Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) exhibits poor clinical response to gemcitabine, largely due to intrinsic and acquired mechanisms of chemoresistance. Identifying agents capable of enhancing gemcitabine efficacy without i...

Background: The plant-derived compound n-butylidenephthalide (BP) is an isobenzofuranone that has shown neuropharmacological effects on preclinical models of Parkinson’s, Alzheimer’s, and amyotrophic lateral sclerosis. Methods: This study...

Silver nanoparticles (AgNPs) have been studied extensively in recent years due to their biological activities. In addition to their well-known antibacterial, antioxidant, and anti-inflammatory properties, AgNPs also exhibit anticancer properties. Inc...

Objectives: The study explores the comparative effects of atorvastatin (ATV), policosanol (PCO), and their combination (ATV+PCO) on metabolic stress and associated organ damage in hyperlipidemic–hyperglycemic zebrafish. Methodology: Hyperlipide...

Background/Objectives: Canagliflozin (CFZ) is the first sodium glucose co-transporter 2 (SGLT-2) inhibitor and is characterized by poor water solubility and permeability, resulting in low oral bioavailability. In this study, a CFZ nanosuspension (CFZ...

Background/Objectives: Pyrazole carboxamides are widely used as adaptable medicinal-chemistry scaffolds and have been explored as cholinesterase (ChE) inhibitor chemotypes. In this work, we prepared a new series of 4-arylazo-3,5-diamino-N-tosyl-1H-py...

Background/Objectives: Interleukin-17A (IL-17A) is a key pathogenic cytokine in autoimmune arthropathies. Current monoclonal antibody inhibitors targeting the IL-17/IL-17RA axis demonstrate clinical efficacy but face significant limitations, includin...

Background: The pathogenesis of rheumatoid arthritis (RA) is closely related to multiple disorders in the immune and metabolic systems, which indicates that a multi-target therapy strategy may have advantages over traditional single-target therapy. H...